Cantor Fitzgerald initiated coverage of Design Therapeutics (DSGN) with an Overweight rating. The firm expects DT-216P2, the company’s lead asset which is designed to elicit improvements in endogenous frataxin production for Friedreich’s ataxia, to continue to show clean safety and for some patients to see 20%-30%+ improvement in frataxin protein levels in the blood, the analyst tells investors in a research note. DT-216P2 is the clear near-term value driver of the Design Therapeutics story, the firm says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Trump approves plan to fire FDA head Marty Makary, CBS reports
- Design Therapeutics price target raised to $21 from $18 at Oppenheimer
- Design Therapeutics price target raised to $20 from $12 at Piper Sandler
- Design Therapeutics reports Q1 EPS (29c), consensus (33c)